or Try an Advanced Search...

    Technical Analysis for PLUR - Pluri Inc.

    Grade Last Price % Change Price Change
    D 6.27 2.96% 0.18
    PLUR closed up 2.96 percent on Thursday, May 16, 2024, on 14 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Up
    Historical PLUR trend table...
    Date Alert Name Type % Chg
    Crossed Above 50 DMA Bullish 0.00%
    Upper Bollinger Band Walk Strength 0.00%
    Wide Bands Range Expansion 0.00%
    Overbought Stochastic Strength 0.00%
    Upper Bollinger Band Touch Strength 0.00%
    Fell Below 50 DMA Bearish 2.96%
    Stochastic Sell Signal Bearish 2.96%
    Spinning Top Other 2.96%
    Weak + Overbought Other 2.96%
    Wide Bands Range Expansion 2.96%
    Older End-of-Day Signals for PLUR ...

       Recent Intraday Alerts

    Alert Time
    Rose Above Previous Day's High about 3 hours ago
    Rose Above Upper Bollinger Band about 3 hours ago
    Rose Above 50 DMA about 3 hours ago
    Up 5% about 3 hours ago
    Up 3% about 3 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    PLUR Chart by TradingView
    Basic chart:

    Profile

    Pluri Inc. Description

    Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Life Sciences Surgery Stem Cell Cell Therapy Radiation Transplantation Inflammatory Transplantation Medicine Host Disease Acute Respiratory Distress Syndrome Graft Versus Host Disease Covid 19 Cell Therapy Products Surgical Oncology

    Is PLUR a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 2 Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment
    Apr 8 Pluri stock jumps 9% on US patent for immune cell production
    Apr 8 Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method
    Mar 27 Pluri to implement a 1-for-8 reverse stock split
    Mar 27 Pluri Inc. Announces 1-for-8 Reverse Share Split
    Mar 21 Pluri’s Sustainable Cell-Based Coffee Addresses Critical Challenges Revealed in International Coffee Organization Market Report
    Mar 14 Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing
    Mar 11 Pluri™ Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation
    Mar 6 Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board
    Feb 28 Pluri’s Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 Goals
    See more PLUR news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 8.56
    52 Week Low 3.4488
    Average Volume 32,079
    200-Day Moving Average 5.35
    50-Day Moving Average 6.23
    20-Day Moving Average 5.62
    10-Day Moving Average 5.99
    Average True Range 0.46
    RSI (14) 58.51
    ADX 15.92
    +DI 24.59
    -DI 14.37
    Chandelier Exit (Long, 3 ATRs) 5.17
    Chandelier Exit (Short, 3 ATRs) 6.09
    Upper Bollinger Bands 6.52
    Lower Bollinger Band 4.73
    Percent B (%b) 0.86
    BandWidth 31.81
    MACD Line 0.10
    MACD Signal Line -0.03
    MACD Histogram 0.1245
    Fundamentals Value
    Market Cap 260.08 Million
    Num Shares 41.5 Million
    EPS -0.71
    Price-to-Earnings (P/E) Ratio -8.83
    Price-to-Sales 127.00
    Price-to-Book 3.62
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 7.06
    Resistance 3 (R3) 7.06 6.79 6.93
    Resistance 2 (R2) 6.79 6.59 6.79 6.88
    Resistance 1 (R1) 6.53 6.47 6.66 6.53 6.84
    Pivot Point 6.27 6.27 6.33 6.27 6.27
    Support 1 (S1) 6.00 6.06 6.14 6.01 5.70
    Support 2 (S2) 5.74 5.94 5.74 5.66
    Support 3 (S3) 5.48 5.74 5.61
    Support 4 (S4) 5.48